VISTARIL

Compare VISTARIL  to:
Compare
Compare

Generic Name for VISTARIL

Hydroxyzine pamoate 25mg, 50mg; caps.

Legal Classification:

Rx

Pharmacological Class for VISTARIL

Antihistamine.

Manufacturer of VISTARIL

Pfizer Labs

Indications for VISTARIL

Allergic pruritus.

Adult dose for VISTARIL

25mg 3–4 times daily.

Children's dosing for VISTARIL

<6 years: 50mg daily. ≥6 years: 50–100mg daily. Both in divided doses.

Also:

Contraindications for VISTARIL

Early pregnancy. Nursing mothers.

Warnings/Precautions for VISTARIL

Elderly.

Interactions for VISTARIL

Potentiates CNS depression with alcohol, other CNS depressants (eg, meperidine, barbiturates).

Adverse Reactions for VISTARIL

Drowsiness, dry mouth, tremor, convulsions.

How is VISTARIL supplied?

Caps—100
Susp—4 oz, pt

Related Disease:

Allergy~systemic antiallergic drugs
Pruritus~antihistamine, systemic

Related Resources

McNeil Consumer Healthcare product supply update

June 25, 2010

McNeil Consumer Healthcare announced that it does not anticipate having sources of supply for most of the products that were produced at its Fort Washington, Pennsylvania manufacturing facility before the end of 2010.

Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray recalled

June 24, 2010

Procter & Gamble announced a voluntary nationwide recall of Vicks Sinex VapoSpray 4-Hour Decongestant Nasal Spray (oxymetazoline HCl).

McNeil recalls Benadryl Allergy Ultratab and Extra Strength Tylenol Rapid Release Gels

June 16, 2010

McNeil Consumer Healthcare has expanded its January 15, 2010 recall to include four lots of Benadryl Allergy (diphenhydramine) Ultratab Tablets and one lot of Extra Strength Tylenol (acetaminophen) Rapid Release Gels.

FDA warns against swallowing topical Benadryl gel

May 12, 2010

The FDA is warning consumers about potentially serious side effects from mistakenly swallowing McNeil Consumer & Specialty Pharmaceuticals' Benadryl (diphenhydramine) Extra Strength Itch Stopping Gel.

FDA launches "Bad Ad Program" to detect misleading drug ads

May 11, 2010

The FDA's Division of Drug Marketing, Advertising, and Communications (DDMAC) has launched the Bad Ad Program, designed to educate healthcare providers about their role in ensuring that prescription drug advertising and promotion is truthful, and not misleading.

This material may not be published, broadcast, rewritten or redistributed in any form without prior authorization.

Your use of this website constitutes acceptance of Haymarket Media's Privacy Policy and Terms & Conditions